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Résumé en
anglais
Paclitaxel-loaded lipid nanocapsules (PX-LNC) exhibit interesting in vitro
characteristics with improved antitumoral activity compared with free PX
formulation. Biodistribution studies were realized with the use of 14C-trimyristin
(14C-TM) or 14C-phosphatidylcholine (14C-PC) whereas antitumoral activity of PX-
LNC formulations was based on the animal survival in a chemically induced
hepatocellular carcinoma (HCC) model in Wistar rats. Blood concentration–time
profiles for both labeled 14C-TM-LNC and 14C-PC-LNC were similar; the t1/2 and
MRT values (over 2 h and close to 3 h, respectively, for both formulations) indicated
the long circulating properties of the LNC carrier with a slow distribution and
elimination phase. Survival curves of paclitaxel treated groups showed a statistical
significant difference compared to the control survival curve (P = 0.0036 and
0.0408). Animals treated with 4× 70 mg/m2 of PX-LNC showed the most significant
increase in mean survival times compared to the controls (ISTmean 72%) and cases
of long-term survivors were preferentially observed in the PX-LNC treated group
(37.5%; 3/8). These results demonstrate the great interest to use LNC as drug
delivery system for paclitaxel, permitting with an equivalent therapeutic efficiency
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